Literature DB >> 19566550

Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM-1VWD study.

J Eikenboom1, L Hilbert, A S Ribba, A Hommais, D Habart, S Messenger, A Al-Buhairan, A Guilliatt, W Lester, C Mazurier, D Meyer, E Fressinaud, U Budde, K Will, R Schneppenheim, T Obser, O Marggraf, E Eckert, G Castaman, F Rodeghiero, A B Federici, J Batlle, J Goudemand, J Ingerslev, S Lethagen, F Hill, I Peake, A Goodeve.   

Abstract

BACKGROUND: Candidate von Willebrand factor (VWF) mutations were identified in 70% of index cases in the European study 'Molecular and Clinical Markers for the Diagnosis and Management of type 1 von Willebrand Disease'. The majority of these were missense mutations.
OBJECTIVES: To assess whether 14 representative missense mutations are the cause of the phenotype observed in the patients and to examine their mode of pathogenicity.
METHODS: Transfection experiments were performed with full-length wild-type or mutant VWF cDNA for these 14 missense mutations. VWF antigen levels were measured, and VWF multimer analysis was performed on secreted and intracellular VWF.
RESULTS: For seven of the missense mutations (G160W, N166I, L2207P, C2257S, C2304Y, G2441C, and C2477Y), we found marked intracellular retention and impaired secretion of VWF, major loss of high molecular weight multimers in transfections of mutant constructs alone, and virtually normal multimers in cotransfections with wild-type VWF, establishing the pathogenicity of these mutations. Four of the mutations (R2287W, R2464C, G2518S, and Q2520P) were established as being very probably causative, on the basis of a mild reduction in the secreted VWF or on characteristic faster-running multimeric bands. For three candidate changes (G19R, P2063S, and R2313H), the transfection results were indistinguishable from wild-type recombinant VWF and we could not prove these changes to be pathogenic. Other mechanisms not explored using this in vitro expression system may be responsible for pathogenicity.
CONCLUSIONS: The pathogenic nature of 11 of 14 candidate missense mutations identified in patients with type 1 VWD was confirmed. Intracellular retention of mutant VWF is the predominant responsible mechanism.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19566550     DOI: 10.1111/j.1538-7836.2009.03486.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  26 in total

Review 1.  Genetic sequence analysis of inherited bleeding diseases.

Authors:  Flora Peyvandi; Tom Kunicki; David Lillicrap
Journal:  Blood       Date:  2013-10-11       Impact factor: 22.113

2.  The molecular basis of von Willebrand disease: the under investigated, the unexpected and the overlooked.

Authors:  Daniel J Hampshire; Anne C Goodeve
Journal:  Haematologica       Date:  2011-06       Impact factor: 9.941

3.  Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels.

Authors:  Michelle Lavin; Sonia Aguila; Sonja Schneppenheim; Niall Dalton; Kenneth L Jones; Jamie M O'Sullivan; Niamh M O'Connell; Kevin Ryan; Barry White; Mary Byrne; Marie Rafferty; Mairead M Doyle; Margaret Nolan; Roger J S Preston; Ulrich Budde; Paula James; Jorge Di Paola; James S O'Donnell
Journal:  Blood       Date:  2017-09-15       Impact factor: 22.113

4.  Functional characterisation of the type 1 von Willebrand disease candidate VWF gene variants: p.M771I, p.L881R and p.P1413L.

Authors:  Ergul Berber; Mehmet Ozbil; Christine Brown; Zafer Baslar; S Hande Caglayan; David Lillicrap
Journal:  Blood Transfus       Date:  2016-07-25       Impact factor: 3.443

5.  Biogenesis of Weibel-Palade bodies in von Willebrand's disease variants with impaired von Willebrand factor intrachain or interchain disulfide bond formation.

Authors:  Jiong-Wei Wang; Dafna J Groeneveld; Guy Cosemans; Richard J Dirven; Karine M Valentijn; Jan Voorberg; Pieter H Reitsma; Jeroen Eikenboom
Journal:  Haematologica       Date:  2011-12-29       Impact factor: 9.941

6.  Mutations in the D'D3 region of VWF traditionally associated with type 1 VWD lead to quantitative and qualitative deficiencies of VWF.

Authors:  Tara C White-Adams; Christopher J Ng; Paula M Jacobi; Sandra L Haberichter; Jorge A Di Paola
Journal:  Thromb Res       Date:  2016-08-10       Impact factor: 3.944

7.  Insights into pathological mechanisms of missense mutations in C-terminal domains of von Willebrand factor causing qualitative or quantitative von Willebrand disease.

Authors:  Hamideh Yadegari; Julia Driesen; Anna Pavlova; Arijit Biswas; Vytautas Ivaskevicius; Robert Klamroth; Johannes Oldenburg
Journal:  Haematologica       Date:  2013-03-28       Impact factor: 9.941

8.  Identification and characterisation of mutations associated with von Willebrand disease in a Turkish patient cohort.

Authors:  Daniel J Hampshire; Adel M Abuzenadah; Ashley Cartwright; Nawal S Al-Shammari; Rachael E Coyle; Michaela Eckert; Ahlam M Al-Buhairan; Sarah L Messenger; Ulrich Budde; Türkiz Gürsel; Jørgen Ingerslev; Ian R Peake; Anne C Goodeve
Journal:  Thromb Haemost       Date:  2013-05-23       Impact factor: 5.249

9.  VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease.

Authors:  Jeroen Eikenboom; Augusto B Federici; Richard J Dirven; Giancarlo Castaman; Francesco Rodeghiero; Ulrich Budde; Reinhard Schneppenheim; Javier Batlle; Maria Teresa Canciani; Jenny Goudemand; Ian Peake; Anne Goodeve
Journal:  Blood       Date:  2013-01-24       Impact factor: 22.113

10.  p.P2063S: a neutral VWF variant masquerading as a mutation.

Authors:  Daniel J Hampshire; Anne C Goodeve
Journal:  Ann Hematol       Date:  2013-06-18       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.